Nurix Therapeutics NRIX
$12.85 −$0.75 (-5.51%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.85 0.00%
Open$13.40
Prev close$13.60
Day range$12.83 – $13.67
Volume2.43M
Market cap$1.40B
P/E (TTM)5.3
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Aug 2026
Revenue$673.06M+8,426.3% YoY
Operating profit$559.45M+712.2% YoY
Net profit$549.81M+736.2% YoY
Diluted EPS$4.73+559.2% YoY
Free cash flow$614.24M+1,122.1% YoY
Operating cash flow$615.63M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin41.3%
Net margin42.0%
Return on equity44.0%
Return on assets34.3%
Return on invested capital37.9%
Current ratio8.44
Liabilities / assets19.0%
Cash & investments$1.05B
Total debt$62.09M
Net cash (debt)$986.16M
Free cash flow / sales52.7%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $673.06M | $9.04M | $6.25M | $83.98M | $13.58M |
| Total Operating Revenue | $673.06M | $9.04M | $6.25M | $83.98M | $13.58M |
| Operating Expense | $113.61M | $103.25M | $98.75M | $369.65M | $96.67M |
| Selling and Admin Expenses | $34.35M | $15.59M | $14.61M | $52.74M | $13.65M |
| -General & Admin Expense | $34.35M | $15.59M | $14.61M | $52.74M | $13.65M |
| Research & Development | $79.26M | $87.65M | $84.14M | $316.90M | $83.02M |
| Operating Profit | $559.45M | -$94.20M | -$92.50M | -$285.67M | -$83.10M |
| Net Non-Operating Interest Income (Expense) | $3.96M | $4.40M | $5.32M | $21.97M | $4.87M |
| Non-Operating Interest Income | $3.96M | $4.40M | $5.32M | $21.97M | $4.87M |
| Pretax Profit | $563.41M | -$89.81M | -$87.17M | -$263.70M | -$78.22M |
| Tax | $13.61M | -$271,000.00 | – | $760,000.00 | $0.00 |
| Net Profit | $549.81M | -$89.54M | -$87.17M | -$264.46M | -$78.22M |
| Profit from Continuing Operations | $549.81M | -$89.54M | -$87.17M | -$264.46M | -$78.22M |
| Net Income to Parent Company | $549.81M | -$89.54M | -$87.17M | -$264.46M | -$78.22M |
| Net Income to Common Stockholders | $549.81M | -$89.54M | -$87.17M | -$264.46M | -$78.22M |
| Basic EPS | $4.93 | -$0.81 | -$0.79 | -$3.05 | -$0.82 |
| Diluted EPS | $4.73 | -$0.81 | -$0.79 | -$3.05 | -$0.82 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.20B | $535.54M | $636.13M | $688.14M | $688.14M |
| Total Current Assets | $1.10B | $456.48M | $554.39M | $606.82M | $606.82M |
| Cash and Cash Equivalents & Short-Term Investments | $1.05B | $443.53M | $540.73M | $592.94M | $592.94M |
| -Cash and Cash Equivalents | $720.24M | $67.69M | $71.20M | $246.96M | $246.96M |
| -Short Term Investments | $328.01M | $375.84M | $469.54M | $345.98M | $345.98M |
| Receivables | $20.00M | – | – | – | – |
| -Accounts Receivable | $20.00M | – | – | – | – |
| Other Current Assets | $35.44M | $12.95M | $13.66M | $13.88M | $13.88M |
| Total Non-Current Assets | $91.61M | $79.06M | $81.74M | $81.32M | $81.32M |
| Net PPE | $68.04M | $70.11M | $73.35M | $73.01M | $73.01M |
| -Gross PPE | $111.51M | $111.46M | $113.08M | $110.79M | $110.79M |
| -Accumulated Depreciation | -$43.47M | -$41.34M | -$39.72M | -$37.78M | -$37.78M |
| Investments and Advances | $14.83M | – | – | – | – |
| -Available for Sale Securities | $14.83M | – | – | – | – |
| Other Non-Current Assets | $8.74M | $8.95M | $8.38M | $8.31M | $8.31M |
| Total Liabilities | $226.99M | $132.91M | $155.24M | $149.39M | $149.39M |
| Total Current Liabilities | $130.74M | $72.02M | $92.20M | $86.47M | $86.47M |
| Payables | $46.93M | $12.46M | $11.33M | $12.27M | $12.27M |
| -Accounts Payable | $32.98M | $12.21M | $10.29M | $11.22M | $11.22M |
| -Total Tax Payable | $13.95M | $247,000.00 | $1.04M | $1.06M | $1.06M |
| Current Accrued Expenses | $27.98M | $28.27M | $31.12M | $30.16M | $30.16M |
| Short-Term Debt and Capital Lease Obligation | $3.24M | $3.22M | $3.20M | $2.82M | $2.82M |
| -Current Capital Lease Obligation | $3.24M | $3.22M | $3.20M | $2.82M | $2.82M |
| Current Deferred Liabilities | $30.84M | $13.32M | $18.75M | $17.58M | $17.58M |
| Other Current Liabilities | $1.49M | $1.30M | $1.93M | $2.10M | $2.10M |
| Total Non-Current Liabilities | $96.25M | $60.89M | $63.04M | $62.92M | $62.92M |
| Long Term Debt and Capital Lease Obligation | $62.09M | $54.92M | $55.45M | $52.91M | $52.91M |
| -Long Term Capital Lease Obligation | $62.09M | $54.92M | $55.45M | $52.91M | $52.91M |
| Non-Current Deferred Liabilities | $34.15M | $5.97M | $7.59M | $10.01M | $10.01M |
| Total Equity | $968.31M | $402.63M | $480.89M | $538.75M | $538.75M |
| Stockholders' Equity | $968.31M | $402.63M | $480.89M | $538.75M | $538.75M |
| Capital Stock | $109,000.00 | $104,000.00 | $103,000.00 | $102,000.00 | $102,000.00 |
| -Common Stock | $109,000.00 | $104,000.00 | $103,000.00 | $102,000.00 | $102,000.00 |
| -Preferred Stock | $0.00 | $0.00 | – | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.60B | $1.58B | $1.57B | $1.54B | $1.54B |
| Retained Earnings | -$630.13M | -$1.18B | -$1.09B | -$1.00B | -$1.00B |
| Gains/Losses Not Affecting Retained Earnings | -$210,000.00 | -$145,000.00 | $56,000.00 | $105,000.00 | $105,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $615.63M | -$96.57M | -$71.91M | -$249.47M | -$67.83M |
| Net cash flow from continuing operations | $615.63M | -$96.57M | -$71.91M | -$249.47M | -$67.83M |
| Net Income from Continuing Operations | $549.81M | -$89.54M | -$87.17M | -$264.46M | -$78.22M |
| Gain/Loss from Continuing Operations | $0.00 | $0.00 | $160,000.00 | $89,000.00 | – |
| Depreciation & Depletion & Amortization | $3.62M | $3.85M | $3.78M | $18.86M | $4.63M |
| Change in Working Capital | $52.37M | -$20.72M | $3.90M | -$31.60M | -$1.55M |
| -Change in Receivables | -$20.00M | – | – | – | – |
| -Change in Prepaid Assets | -$13.56M | $263,000.00 | $1.29M | -$6.23M | -$1.28M |
| -Change in Payables and Accrued Expense | $41.04M | -$13.38M | $3.66M | $16.68M | $14.07M |
| -Change in Other Current Liabilities | -$809,000.00 | -$557,000.00 | $205,000.00 | -$5.07M | -$756,000.00 |
| -Change In Other Working Capital | $45.70M | -$7.04M | -$1.25M | -$36.98M | -$13.58M |
| Net cash flow from investing | $31.58M | $93.00M | -$123.83M | $147.85M | $346,000.00 |
| Net Cash Flow from Continuing Investing Activities | $31.58M | $93.00M | -$123.83M | $147.85M | $346,000.00 |
| Net PPE Purchase and Sale | -$1.39M | -$1.94M | -$1.05M | -$14.00M | -$5.13M |
| Net Investment Purchase and Sale | $32.97M | $94.93M | -$122.78M | $161.86M | $5.48M |
| Financing Cash Flow | $5.16M | $66,000.00 | $19.98M | $238.64M | $236.01M |
| Net Cash Flow from Continuing Financing Activities | $5.16M | $66,000.00 | $19.98M | $238.64M | $236.01M |
| Net Common Stock Issuance | $0.00 | $0.00 | $18.00M | $234.76M | $234.76M |
| Proceeds from Stock Option Exercised | $5.16M | $66,000.00 | $1.97M | $3.88M | $1.25M |
| Ending Cash Balance | $721.02M | $68.65M | $72.16M | $247.93M | $247.93M |
| Net Change in Cash | $652.37M | -$3.51M | -$175.77M | $137.03M | $168.52M |
| Beginning Cash Balance | $68.65M | $72.16M | $247.93M | $110.90M | $79.41M |
| Free Cash Flow | $614.24M | -$98.51M | -$72.96M | -$263.47M | -$72.96M |
No comments yet — be the first to weigh in on NRIX.
Sign in to join the discussion.